Ann: Shareholder Information Sessions, page-24

Firstly to HCI, what a great idea, that had not occurred to me. Don't know that I will act on it though, because if mcees is correct mine will be snapped up by some other lucky investor. [No, I am not taking up the offer for the simple reason that I already have enough spondoolah tied up in speculative investments and I am sticking with what I have got every which way (diversification).] If ADO reaches the magical $1, which was my initial (and still is) hope, I will be well satisfied and not bemoaning the fact that I refused a golden opportunity to get 5% more.

I think I can say that my post generated some very worthwhile comment. That is what a forum such as this is all about. It's genesis came from a sentiment gleaned from remarks made by others on the NEU forum, who like myself are dual holders. Yes, there are other biotechs - some are even those horrid, binary result driven, FDA reliant mobs who really just sponge off the gullible (read that somewhere here many moons ago) - who can present very compelling cases for their followers. They are all different and each risk/reward must be assessed by the beholder.

As I said there, and I say here, diversification is the key. Attempting to build safety into risk, which is in itself a risky business, but it sure beats the **** out of watching grass grow in the blue chip arena. I'm in ADO, I am sticking with ADO to the glorious future or the bitter, disappointing end, or somewhere in between. At the moment the reality is that we are still somewhere in between.